User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US12427251B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 9, 2022 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Oct 12, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2230/201
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.